for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cognition Therapeutics Inc

CGTX.OQ

Latest Trade

3.70USD

Change

-0.36(-8.87%)

Volume

3,258

Today's Range

3.70

 - 

4.13

52 Week Range

3.14

 - 

13.78

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.06
Open
4.13
Volume
3,258
3M AVG Volume
1.80
Today's High
4.13
Today's Low
3.70
52 Week High
13.78
52 Week Low
3.14
Shares Out (MIL)
22.04
Market Cap (MIL)
81.53
Forward P/E
-2.25
Dividend (Yield %)
--

Latest Developments

More

Cognition Therapeutics Reports Q3 Loss Per Share of $8.12

Cognition Therapeutics Shares Open 1.25% Above IPO Price In Nasdaq Debut

Cognition Therapeutics Inc - Estimated IPO Price Per Share Will Be Between $11 And $13

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cognition Therapeutics Inc

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It is developing a pipeline of small molecule product candidates that are designed to target the sigma-2 receptor (S2R) complex, a regulator of the cellular damage response for diseases, such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA) and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.

Industry

Business Services

Contact Info

2403 Sidney Street, Suite 261

PITTSBURGH, PA

15203

United States

+1.412.4812210

http://www.cogrx.com/

Executive Leadership

Lisa R. Ricciardi

President, Chief Executive Officer, Director

Susan Catalano

Co-Founder, Chief Science Officer, Director

James M. O'Brien

Chief Financial Officer

Stephen Sands

Director

Peggy Wallace

Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-1.643
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up